Werewolf Therapeutics, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation DE
Business Address 200 TALCOTT AVENUE, WATERTOWN, MA, 02472
Mailing Address 200 TALCOTT AVENUE, WATERTOWN, MA, 02472
Phone 617-952-0555
Fiscal Year End 1231
EIN 823523180
Financial Overview
FY2025
$126.93M
Total Assets
$53.54M
Total Liabilities
$111.00M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 27, 2026 | View on SEC |
| 8-K Current report of material events | March 27, 2026 | View on SEC |
| 3 Initial insider ownership report | March 13, 2026 | View on SEC |
| 8-K Current report of material events | February 24, 2026 | View on SEC |
| 8-K Current report of material events | February 13, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 11, 2026 | View on SEC |
| 8-K Current report of material events | February 6, 2026 | View on SEC |
| 4 Insider stock transaction report | January 20, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | January 16, 2026 | View on SEC |
| 4 Insider stock transaction report | January 15, 2026 | View on SEC |
Annual Reports
10-K March 27, 2026
- Proprietary PREDATOR protein engineering platform creates tumor-selective INDUKINE and INDUCER therapies.
- Promising clinical data with WTX-124 showing a 21% response rate and WTX-330 achieving 45% tumor shrinkage.
Material Events
8-K Strategy Change March 27, 2026
High Impact
- Exploring strategic alternatives including potential sale, merger, or partnership
- Proprietary INDUKINE™ platform remains the primary value driver
8-K Financial Distress February 13, 2026
High Impact
- Prioritizing most advanced proprietary INDUKINE™ programs, WTX-124 and WTX-330, currently in preclinical development.
- Actively seeking strategic partnerships, collaborations, or out-licensing opportunities for core programs to maximize value.
8-K Financial Distress February 6, 2026
High Impact
- Werewolf Therapeutics has 180 calendar days, until August 3, 2026, to regain Nasdaq compliance by maintaining a stock price of $1.00 or more for 10 consecutive business days.
- The company may qualify for a second 180-day compliance period if it meets other listing standards, offering an extended timeframe to resolve the issue.
Insider Trading
STRONG SELL 3 insiders
63 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.